Łukasz Puchała, Joanna Wojtkiewicz, Piotr Jakubowski, Waldemar Grzegorzewski
Neuregulin-1 as a potential drug in heart failure – theoretical foundations and the state of clinical trials
Pharmacological treatment of heart failure is based on the use of ACE inhibitors, angiotensin receptor blockers, betablockers and diuretics. The use of recombinant proteins for the treatment of heart failure would be another step in the development of biological drugs and would allow for better results of the current treatment, where mortality remains high and the results of treatment are unsatisfactory. Neuregulin-1 (NRG-1) is an adhesive protein with a complex activity resulting from the presence of isoforms specific to individual locations, inter alia it is a cardioactive growth factor released from endothelial cells, essential for heart development, structural preservation and functional integrity of the heart. NRG-1 and its family of ErbB receptors may play a beneficial role in the treatment of chronic heart failure (CHF) by promoting survival of myocardial myocytes, improving muscle structure, balancing Ca 2+ homeostasis and increasing ejection. The beneficial effect of neuregulin-1 causes that recombinant human neuregulin-1 (rhNRG-1) is a potential drug for the treatment of CHF.
Keywords: New drugs, clinical trials, Neuregulin-1, chronić heart failure, clinical pharmacology
© Farm Pol, 2018, 74 (6): 334–336